Enhancement of anti-tumor immunity in RAS-addicted cancers with tri-complex RAS(ON) inhibitors
Edifici Cluster I, Aula Fèlix Serratosa C/ Baldiri Reixac 10-12, BarcelonaSpeaker: Elsa Quintana, Pharm.D., Ph.D. Senior Director Cancer Immunology, Revolution Medicines, Redwood City, USA RAS mutations (RASMUT), the most frequent oncogenic alterations in human cancers, promote carcinogenesis through sustained cellular proliferation...
